Onterris, Inc. declared a dividend of one preferred share purchase right for each outstanding common share to holders of record on August 17, 2026. The company entered into a Rights Agreement with Computershare Trust Company as rights agent. Each right entitles the holder to purchase one-thousandth of a Series B Preferred Share at $105.00 per unit. The rights will separate from common stock upon the earlier of ten days following a public announcement that an acquirer has obtained 15% or more beneficial ownership, or ten business days after the commencement of such a tender offer. The rights expire on August 4, 2027. Onterris, Inc. operates in the biotechnology industry and develops therapies for rare diseases.

Onterris, Inc. declared a dividend of one preferred share purchase right for each outstanding common share to holders of record on August 17, 2026. The company entered into a Rights Agreement with Computershare Trust Company, N.A., establishing a poison pill defense mechanism. Each right entitles the holder to purchase one-thousandth of a Series B Preferred Share at $105.00 per unit. The rights will separate from common stock and trade independently upon the earlier of ten days following a public announcement that an entity has acquired 15% or more beneficial ownership, or ten business days after the commencement of such a tender offer. If triggered by an 'Acquiring Person,' the rights become exercisable for shares valued at twice the exercise price (flip-in) or allow exchange for acquirer stock in a merger (flip-over). The board may redeem the rights at $0.001 per right prior to any triggering event. Onterris, Inc. operates in the technology sector, providing data analytics and artificial intelligence solutions.

Onterris reported Q2 2026 revenue of $186.7 million and net income of $1.4 million ($0.04 diluted EPS), down from $234.5 million and $18.4 million in the prior year, driven by historically low environmental emergency response activity. The company updated its full-year 2026 revenue guidance to $740–$790 million (from $840–$900 million) and Adjusted EBITDA guidance to $117–$120 million (from $125–$130 million). Onterris announced a Board-led strategic review of its business, portfolio, and capital allocation, including potential acquisition interest. Concurrently, the Board adopted a limited-duration stockholder rights plan effective immediately to protect the integrity of this review process. The company operates in the environmental solutions industry.